Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Monitoring of Vedolizumab Infusion Therapy response with fecal calprotectin, ultrasound and trough serum level in Ulcerative colitis. A multicentric, prospective non-interventional Study - MOVE-IT

Trial Profile

Monitoring of Vedolizumab Infusion Therapy response with fecal calprotectin, ultrasound and trough serum level in Ulcerative colitis. A multicentric, prospective non-interventional Study - MOVE-IT

Status: Recruiting
Phase of Trial: Phase IV

Latest Information Update: 28 May 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Vedolizumab (Primary)
  • Indications Ulcerative colitis
  • Focus Therapeutic Use
  • Acronyms MOVE-IT
  • Most Recent Events

    • 21 May 2019 Status changed from not yet recruiting to recruiting.
    • 12 Nov 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top